Fetuin-A is a serum glycoprotein synthesized and secreted into blood by the liver and whose main physiological function is the inhibition of ectopic calcification [1]. However, a number of recent studies including from our laboratory have indicated that it plays a pivotal role in tumor initiation and progression [2–4]. Other studies have also demonstrated that it as a major serum protein in the sequelae of type-2 diabetes [5–7]. Taken together, fetuin-A is now categorized as a multifunctional protein in normal and pathophysiology of humans [8]. Studies indicate that for fetuin-A to perform some of its physiological functions in tumor cells, it must be internalized. Inside the cells, fetuin-A has the propensity to interact with a number of intracellular proteins such as histones [9]. We have demonstrated that fetuin-A participates in the biogenesis of exosomes that promote adhesion, cell spreading, motility, and invasion [10]. Interestingly, tumor cells that synthesize and secrete fetuin-A can grow albeit less vigorously, in serum-free medium [11].

We have reported using labeled fetuin-A that tumor cells readily take up the protein within 3 min at 37 °C [12]. Others have also demonstrated rapid uptake of fetuin-A by smooth muscle cells [13], even though the uptake mechanism is yet to be defined. Uptake of labeled fetuin-A could not be inhibited by excess unlabelled fetuin-A as would be expected for a canonical cell surface receptor [11,13]. This led to the speculation that perhaps it is taken up by other process such as macro- or micropinocytosis [13]. A recent report

### Keywords
adhesion; endocytosis; fetuin-A; LPS; receptor; TLR4

### Correspondence
J. Ochieng, Meharry Medical College School of Medicine, West Basic Science Building 2106, 1023 21st Ave. N., Nashville, TN 37208, USA
Fax: +1 615 327 6442
Tel: +1 615 327 6119
E-mail: jochieng@mmc.edu

(Received 17 April 2020, revised 21 September 2020, accepted 7 October 2020)

doi:10.1002/2211-5463.13008
demonstrated that fetuin-A is one of a handful of ligands for TLR4 and that it interacts with the extracellular motifs of the receptor via its terminal β-galactosides [14]. This report prompted us to ask the question of whether TLR4 could take part in the uptake mechanisms of fetuin-A in tumor cells. Toll-like receptor-4 is a member of the pattern recognition proteins, whose main established extracellular ligand is lipopolysaccharide (LPS) [15]. In resting immune cells, TLR4 is located in Golgi and plasma membrane. Myeloid differentiation factor (MD2) is an accessory protein that is essential for LPS-mediated activation of TLR4. LPS on the other hand is delivered to TLR4 by another accessory protein CD14 [16]. Apart from LPS and fetuin-A, other ligands that interact with TLR4 have been identified, including hyaluronan [17] and high-mobility group box1 (HMB1) [18]. Signaling via Toll-like receptors (TLRs) orchestrates mainly inflammatory responses that usually accompany innate host defenses against foreign-microorganisms [19]. Interestingly, it is only recently that the exact endocytic uptake and processing mechanisms for TLR4, upon activation was defined [20].

More recent studies implicate TLRs in the progression of a number of tumors [21–23], where the inflammatory responses following the activation of these receptors by their natural ligands such as LPS are thought to be the drivers of transformation and tumor growth. The present study does not refute this dogma, but the data suggest that TLR4 participates in other fundamental adhesion and growth mechanisms of tumor cells.

Using a specific inhibitor for TLR4, CLI-095, we demonstrated that at ~10 μg·mL⁻¹ (100 μm), it inhibits the uptake of labeled fetuin-A. We also knocked down TLR4 in tumor cells that express the receptor and assessed the abilities of parental nonsilencing controls as well as knockdown subclones to take up labeled fetuin-A. We hereby show the interaction of fetuin-A with TLR4 on the surfaces of adhered tumor cells. More importantly, we demonstrate that knockdown of TLR4 as well as CLI-095 was able to effectively inhibit the uptake of labeled fetuin-A by tumor cells. Taken together, the data show that TLR4 expressed by a variety of tumor cells plays a role in the rapid uptake of fetuin-A by these cells.

Materials and methods

Cells

MDA-MB-231, BT-549, and HCC1806 breast cancer as well as PC3 (prostate) and LN229 (glioblastoma) cell lines were purchased from ATCC, Manassas, VA. The breast cancer cell lines were cultured in Dulbecco minimum essential medium supplemented with 10% FBS, while PC3 and LN229 were maintained IMDM supplemented with 10% FBS, containing 1× antibiotic/antimycotic (Life Technologies, Grand Island, NY, USA). The cells were maintained in humidified CO₂ incubator at 37 °C. The serum-free medium (SFM) used in the studies contained 1% (w/v) bovine serum albumin.

Materials

Lipopolysaccharide (LPS) was purchased from Thermo Fisher, Waltham, MA, and CLI-095 from InvivoGen, San Diego, CA, USA. All the other reagents unless otherwise stated were purchased from Sigma-Aldrich, St Louis, MO, USA.

Western Blot analysis

The expression of TLR4 as well as actin controls was performed as previously described [9]. Briefly, whole cell extracts from PC3, MDA-MB-231, and HCC1806 were prepared in radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris/HCl, pH 7.4, 1% NP-40, 0.1% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA, and freshly added protease and phosphatase inhibitor cocktail). Thirty micrograms of protein from each of the cell lines was loaded to 4–12% SDS/PAGE. The protein bands were transferred to a polyvinylidene fluoride membranes. After blocking with 5% nonfat milk, the membranes were incubated with antibodies to either TLR4 or β-actin (Santa Cruz, Dallas, TX, USA) overnight at 4 °C. The membranes were exposed to chemiluminescence (PerkinElmer, PerkinElmer, Waltham, MA, USA), after incubation with the corresponding secondary antibodies for signal detection.

Fetuin-A uptake studies

Fetuin-A purified as described [12] was labeled with rhodamine isothiocyanate as previously described [24]. The labeled protein was separated from unlabeled label by passing twice through a desalting column (HiTrap™, GE Healthcare, Chicago, IL, USA). Cells were grown in chambered glass slides until ~80% confluent. Labeled fetuin-A (1 mg·mL⁻¹) was then added to the chambers (40 μg per chamber) in the absence (vehicle controls) or presence of CLI-095 (10 μg·mL⁻¹) and incubated for exactly 2 min. The cells in the chambers were washed once with Hanks buffered salt solution (HBSS) and then fixed in 4% formalin. The plastic chambers were removed and the slides cover-slipped, examined under a confocal microscope and images acquired digitally. Mean arbitrary units of fluorescence plus or minus SD were quantified using Nikon Elements Advanced Research Software (NEARS).
experiment was repeated 3× using a different cell line each time.

**Fetuin-A mediated cellular adhesion and spreading**

In order to underscore the significance of rapid fetuin-A uptake in anchorage-dependent growth of tumor cells, the breast carcinoma cell line BT-549 was allowed to adhere to plastic in Hanks buffered salt solution (HBSS) in the presence of only 1 mM Ca\(^{2+}\) ions. Under these conditions, integrins are not involved in the adhesion process because they require Mg\(^{2+}\) or Mn\(^{2+}\) ions. The cells (2 × 10⁴ cells per well) were allowed to adhere in 96-well culture plates in HBSS (control); HBSS + fetuin-A and HBSS + fetuin-A + CLI-095 for 2 h at 37 °C. The nonadherent cells were carefully removed and the loosely adhered cells fixed in 4% formalin for 15 min. The cells were then stained with crystal violet as described [25] and images acquired.

**Modulation of cell surface expression of TLR4 by lipopolysaccharide (LPS) and fetuin-A in adhered tumor cells**

Given that fetuin-A is one of the ligands for TLR4, we questioned its potential to modulate the expression of TLR4 on the surfaces of adhered tumor cells by flow-cytometry. To analyze the expression of cell surface TLR4, prostate cancer PC3 cells (~ 70% confluent) were serum starved for 24 h. Lipopolysaccharide was then added to the cells (10 µg·mL\(^{-1}\)) in SFM either in the absence (control) or presence of purified fetuin-A (2 mg·mL\(^{-1}\)). The cells were incubated at 37 °C in humidified CO\(_2\) incubator for 2 h. They were then detached with 2 mM EDTA in PBS containing 0.1% (w/v) sodium azide to slow down translocation of the cell surface receptors. The cells were pelleted and resuspended as single cells in cold FACS buffer (PBS containing 1% BSA and 0.1% sodium azide). They were then transferred to Eppendorf tubes (1 × 10⁶ cells per tube) and incubated without (unlabeled controls) or with Cy5-labeled APC anti-human CD284 (TLR4; BioLegend, San Diego, CA, USA; 10 µL per tube) for 30 min at 4 °C with end on end rotation. The cells were washed 3× with cold FACS buffer and analyzed by BD FACScalibur and the gates for samples determined by single color controls. Unlabeled control cells were used. Data were analyzed on FLOWJO software (TreeStar, TreeStar, San Carlos, CA, USA).

**Dynamic uptake and localization of fetuin-A and TLR4 in intracellular compartments in tumor cells**

**Knockdown of TLR4 in tumor cells**

Prostate cancer PC3 cells were cultured in 6-well plates until cell number approached ~2 × 10⁵ cells per well in 2 mL of DMEM/F-12 and then transfected with nonsilencing control or human TLR4 shRNA in Lenti-GFP using DNAfectin™ Plus as per the manufacturer’s protocol (Applied Biological Materials Inc., Richmond, BC, Canada). The cells were selected in complete medium containing 2.5 µg·mL\(^{-1}\) of puromycin for 4 weeks. Puromycin-resistant and GFP-positive cells were further isolated using fluorescence-activated sorting and thereafter maintained in selection medium. Knockdown was validated by western blot assays. The PC3 nonsilencing control cells (PC3-NSC) and TLR4 knockdown (PC3-C3) cells were added to glass-bottom dishes and incubated for 24 h in complete medium. The medium was replaced with SFM (1 mL per dish) and rhodamine isothiocyanate-labeled fetuin-A (100 µg per dish) added and uptake monitored for 60 s (Nikon A1R). Fetuin-A uptake studies were also undertaken using live glioblastoma LN229 cells. The cells were grown in glass-bottom dishes (Matsunami Glass, Bellingham, WA, USA)
until ~ 80% confluent. The cells were serum starved (in 1 mL of serum-free medium) for 24 h and cells in the dishes prepared for live cell imaging (Nikon A1R). The serum starvation medium was replaced with fresh serum-free medium (SFM), and labeled fetuin-A (100 µg per dish) was added in the absence (control) or presence of CLI-095 (10 µg·mL⁻¹) at 0 time point and images (rhodamine) acquired at 0-, 30-, 60-, and 120-s time points. The control dish contained equivalent volume of DMSO (vehicle control).

**Localization of fetuin-A TLR4 in the intracellular compartments of adhered and spread tumor cells**

MDA-MB-231 breast carcinoma cells were allowed to adhere to chambered glass slides in complete medium for 24 h. The medium was replaced with serum-free medium and rhodamine isothiocyanate-labeled fetuin-A added to the chambers (100 µg per chamber) and incubated for 3 min at 37 °C, washed once with cold PBS, and fixed in cold methanol for 5 min. The cells were washed once more with PBS and incubated with antibodies to TLR4 followed by fluorescein isothiocyanate-labeled secondary antibodies. The chambers were removed, a drop of antifade with DAPI added to the slides, cover-slipped, and examined under a confocal microscope and images acquired.

**Adhesion and invasion of LN 229 cells in the presence of either CLI-095 or asialofetuin-A (ASF)**

Detached LN229 cells were incubated in serum-free medium without (controls) or with either CLI-095 (10 µg·mL⁻¹) or ASF (1 mg·mL⁻¹) for 30 min at 37 °C and then allowed attach to plastic for 24 h in serum-free medium without (vehicle controls) or with CLI-095 (10 µg·mL⁻¹) in DMSO or ASF (1 mg·mL⁻¹), after which the adhered cells were fixed in 4% formalin and stained with crystal violet. The same cells, 250 000 cells per chamber in SFM without (controls) or containing CLI-095, or ASF were added to the upper chambers (Boyden chamber invasion assay) while the lower chambers contained purified fetuin-A (2 mg·mL⁻¹) in SFM. After 24 h, the invading cells migrated to the underside of Matrigel-coated polycarbonate filters. After removing the cells remaining in the upper chambers with cotton swabs, the migrated cells were fixed in 4% formalin and stained with crystal violet as described [24].

**Statistics**

Statistical calculations were performed using GraphPad PRISM 5 software (GraphPad, San Diego, CA, USA). Data were expressed as mean plus or minus standard deviation. P values < 0.05 were considered significant.

**Results**

**Uptake of fetuin-A by tumor cells is attenuated by the TLR4 inhibitor, CLI-095**

We previously demonstrated that fetuin-A is rapidly internalized by adherent tumor cells (~ 3 min) at 37 °C [12]. We now show that this rapid uptake is significantly attenuated by CLI-095, the specific inhibitor of TLR4 in two breast carcinoma cell lines (Fig. 1A) both of which express TLR4 (Fig. 1B). The physiological consequence of rapid uptake of fetuin-A by tumor cells is the biogenesis and secretion of exosomes that mediate rapid cell spreading and adhesion. This is better illustrated under conditions where integrins are minimally involved in the adhesion process. Hence, the cells are allowed to adhere loosely to plastic in the presence of Hanks buffered saline solutions containing only [Ca²⁺]. Under these conditions, control cells that do not synthesize and secrete fetuin-A would not adhere or even spread on plastic. However, in the presence of added fetuin-A, the cells spread and adhere loosely to plastic (Fig. 1C). This requires the rapid uptake of fetuin-A, and therefore, the inhibition of the rapid uptake of fetuin-A by CLI-095 abrogates the adhesion and spreading of cells.

**Fetuin-A downregulates TLR4 expression on the surfaces of adherent tumor cells**

Given that fetuin-A is one of the ligands of TLR4, we questioned whether fetuin-A would influence the cell surface disposition of the receptor relative to its natural ligand, LPS in adherent cells. To do this, we employed Cy5-labeled TLR4 monoclonal antibody. As shown in Fig. 2, serum-free medium containing only 1% BSA supports the baseline surface expression of TLR4, and interaction with its natural ligand LPS, and appears to slightly upregulate its expression on the surfaces of adherent prostate cancer (PC3) cells. However, in the presence of purified fetuin-A (2 mg·mL⁻¹) and LPS, the surface expression of TLR4 in adherent cells PC3 cells was downregulated almost 2-fold. The experiments were repeated 3× with similar data.

**TLR4 inhibitor, CLI-095, traps the receptor on the cell surface**

Whereas the internalization of most cell surface receptors is a means of signal silencing, the internalization of TLR4 is a requirement for activation [20]. We therefore questioned whether the TLR4 inhibitor, CLI-095, would interfere with its endocytic uptake
(activation) and or redistribution and confine it to the cell surface in adherent cells. Adhered cells in the presence of purified fetuin-A (2 mg/mL) or medium containing 10% FBS had negligible surface expression of TLR4. Most of the TLR4 were in intracellular compartments (Fig. 3A; upper panels). However, in the presence of fetuin-A (2 mg/mL) or complete medium and CLI-095 (10 µg/mL), cell surface expression of TLR4 was increased almost 10-fold (Fig. 3A, lower panels), further suggesting that CLI-095 attenuates the internalization of TLR4. The experiment was repeated with PC-3 cells where the presence of CLI-095 in SFM also resulted in a drastic increase in the cell surface expression of TLR4 (Fig. 3C) relative to SFM control (Fig. 3B).

**Time course of rapid uptake of fetuin-A by tumor cells**

We next wanted to determine the fetuin-A uptake in real time both in the TLR4 knockdown PC3 cells and in the LN229 glioblastoma cells in the absence and presence of CLI-095. The fetuin-A uptake in nonsilencing control PC3 cells was quite rapid (within 60 s) but not in the TLR4 knockdown (PC3-C3) where the labeled fetuin-A was concentrated on the cell surface instead (Fig. 4A). The expression of TLR4 in PC3 and its knockdown subclone is depicted in Fig. 4B. The clones in which the TLR4 knockdown was >80% did not survive beyond passage 1, underscoring the significance of TLR4 in the growth of tumor cells. The fetuin-A uptake was similarly rapid in control LN229 glioblastoma cells (~60 s). However, in the presence of CLI-095 as suspected, there was no uptake even after 120 s (Fig. 4C). Both fetuin-A and TLR4 are localized mainly in intracellular compartments (perinuclear) in adhered and spread cells. They are clearly colocalized in some cells (yellow; white arrows) while in other cells they appear to be colocalized in the nucleus (white; green arrow; Fig. 4D). Interestingly, the appearance of both fetuin-A and TLR4 in the nucleus has been reported [9,25].

**TLR4 inhibitor, CLI-095, attenuates both adhesion and invasion potentials of glioblastoma cell line, LN229**

Incubation of the detached cells with CLI-095 or asialofetuin-A (ASF) severely compromised their
Fig. 2. Fetuin-A downregulates cell surface expression of TLR4 in adhered and spread cells. Prostate cancer PC3 cells were grown in 75-CM² culture flasks until ~70% confluent. Complete medium was replaced with serum-free medium containing 1% BSA for 24 h. Serum-free medium was replaced with fresh SFM without (B) or with lipopolysaccharide (LPS) (10 µg·mL⁻¹) (C) or with LPS (10 µg·mL⁻¹) and fetuin-A (2 mg·mL⁻¹) (D) and incubated at 37 °C in humidified CO₂ incubator for 2 h. The cells were washed with PBS once and then detached with 2 mM EDTA in PBS containing 0.1% sodium azide. The cells were washed once with cold FACS buffer (PBS, 1% BSA, 0.1% NaN₃), pelleted, and resuspended in 1 mL of cold FACS buffer in Eppendorf tubes (1 × 10⁶ cells per tube) and incubated without (A; unlabeled controls), or with CY5-labeled anti-human CD284 (TLR4) (10 µL per tube) for 30 min with end on end rotation at 4 °C. The cells were washed (3×) with cold FACS buffer and resuspended in the same buffer and analyzed by BD FACScalibur.
abilities to adhere and spread on plastic (Fig. 5A). LN229 synthesize and secrete fetuin-A [11]. In the controls, the fetuin-A can then be taken up via TLR4 to promote adhesion, while in CLI-095-treated cells, fetuin-A uptake is inhibited and consequently adhesion is attenuated. Previous data suggested that asialofetuin-A competed with fetuin-A for binding to the putative receptor [11]. Given that ASF has terminal β-galactosides that are not hindered by the sialic acid residues, it appears to interact and bind more efficiently to TLR4. We demonstrated that it also enters tumor cells rapidly and acts as a dominant-negative inhibitor of fetuin-A-mediated functions in tumor cells [11]. The presence of either CLI-095 or ASF in the upper chambers of the Boyden apparatus attenuates the capacity of the cells to interact with the Matrigel, thereby slowing and minimizing the process of invasion (Fig. 5B).

**Discussion**

We previously demonstrated the rapid uptake of fetuin-A by tumor cells which resulted in the biogenesis of exosomes that mediated adhesion, motility, and invasion [10]. We, however, were not able to elucidate the mechanism(s) by which fetuin-A was rapidly internalized. We hereby provide experimental evidence that TLR4 participates in the rapid uptake of fetuin-A by tumor cells resulting in rapid attachment and spreading of cells on substrata. The experiments were performed using multiple tumor cell lines to underscore the significance of fetuin-A and TLR4 in the *in vitro* growth of these cells.
The abrogation of rapid endocytic uptake of fetuin-A by the TLR4 inhibitor, CLI-095 as well as knockdown of the receptor in tumor cells, demonstrates that TLR4 plays a central role in the physiological functions of fetuin-A particularly in tumor cells. Of note was the fetuin-A-mediated downregulation of the surface expression of TLR4 in the adhered and spread tumor cells. Lipopolysaccharide (LPS), the natural ligand of TLR4 by itself, was not able to promote the translocation of the TLR4 from the cell surface to endosomal compartments as expected. Thus, the low surface expression of TLR4 on the surfaces of tumor cells growing in culture plates could be due to fetuin-A which is present in most growth media supplemented with 10% fetal bovine serum. The data suggest that fetuin-A and TLR4 comigrate into intracellular compartments. The rapid uptake of fetuin-A by adherent tumor cells is necessary for their growth and survival. Reduced levels or absence of fetuin-A in the growth media or tumor microenvironment results in slow and poor growth of tumor cells in vitro and in vivo [3,4,11]. Fetuin-A mediates optimal cellular adhesion and spreading on various substrata not only in vitro but also in vivo, thereby promoting anchorage-dependent cellular proliferation. The rapid uptake of fetuin-A initiates the biogenesis and secretion of exosomes that promote cell spreading and rapid adhesion [10,26].

The accumulation of TLR4 on the surfaces of adherent cells in the presence of its inhibitor, CLI-095, provided further evidence that activated TLR4 drives the uptake of fetuin-A into intracellular compartments. CLI-095, which associates with the cytosolic domain of the receptor, inactivates it, and consequently, it is not endocytosed [20]. In immune cells, LPS first binds to the GPI-anchored CD14 which then transfers LPS to cell surface MD-2 which then dimerizes TLR4 to be trafficked into endosomal compartments followed by the activation process of TLR4 [20]. Because fetuin-A

---

**Fig. 4.** Dynamic uptake and localization of fetuin-A and TLR4 in intracellular compartments in tumor cells. In (A), PC3 prostate cancer nonsilencing control (PC3-NSC) and TLR4 knockdown (PC3-C3) cells were added to glass-bottom dishes and incubated for 24 h in complete medium. The medium was replaced with SFM (1 mL per dish) and rhodamine isothiocyanate-labeled fetuin-A (100 µg per dish) added and uptake monitored for 60 s (Nikon A1R). In (B), the expression of TLR4 in PC3-NSC and PC3-C3. In (C), the glioblastoma LN229 cells were added to glass-bottom petri dishes in complete medium and incubated for 24 h at 37°C (~80% confluence). The medium was replaced with SFM (1 mL per dish) containing either 100 µL per dish of DMSO (vehicle control) or CLI-095 (10 µg·mL⁻¹; 100 µL per dish). To control and experimental dishes, 100 µg per dish of rhodamine isothiocyanate-labeled fetuin-A was added at time 0 s and uptake by the live cells monitored using confocal microscope (Nikon A1R) for up to 120 s. In (D), rhodamine isothiocyanate-labeled fetuin-A was added to MDA-MB-231 breast carcinoma cells adhered to glass-chambered slides, incubated for 2 min at 37°C, washed once with cold PBS, and fixed in cold methanol for 5 min. The cells were washed once more with PBS and incubated with antibodies to TLR4 followed by fluorescein isothiocyanate-labeled secondary antibodies (green). The chambers were removed and the slides processed as described in Materials and Methods. Scale bars = 100 µm.
also interacts with extracellular domains of TLR4 [14], it is tempting to speculate that in the absence or low levels of expression of MD-2, fetuin-A may promote the dimerization of TLR4 as a primer for endocytic uptake where the two molecules comigrate into endosomal compartments. The present studies made it clear that activation of TLR4 is essential for not only the trafficking of TLR4 into the intracellular compartments including the nucleus, but also for fetuin-A which can also be trafficked into the nucleus [9]. The role of fetuin-A in the growth of cells in culture either directly or indirectly has been debated ever since its discovery over 70 years ago [5,27–29]. Assuming that the rapid uptake of fetuin-A by cells is part of its growth-promoting process, the present data suggest that TLR4 plays other functional roles in tumor cells that do not involve inflammatory responses. Indeed, a number of studies have implicated TLR4 to be involved in key growth and antiapoptotic signaling mechanisms in tumor cells [30,31].

The potential role(s) of fetuin-A in tumor progression is currently of significant interest. Recently, a system biological approach study indicated that fetuin-A is a significant molecular determinant of metastasis [32]. Fetuin-A has also been suggested to be a determinant of prostate cancer metastasis [2] and a key molecule in the etiology of male breast cancer [33]. In Boyden chamber assays for motility and invasion, medium containing 10% fetal bovine serum is generally added to the bottom chambers as chemoattractant. We previously reported that purified fetuin-A at a concentration of ~2 mg·mL⁻¹ can also be used as a chemoattractant in such assays [34]. Interestingly, the concentration of fetuin-A in medium containing 10% fetal bovine serum is ~2 mg·mL⁻¹.

In summary, we have provided evidence that TLR4 participates in the rapid uptake of fetuin-A by tumor cells and that inhibition of TLR4 activation by a specific inhibitor of the receptor attenuates the fetuin-A mediated physiological events in tumor cells such as rapid adhesion, cell spreading, invasion, and growth on the substrata.

Acknowledgments

This work was supported by U54 MD007586-03 (JO) (CRISALIS), U54 CA163069 (AS), SC1 CA182843 (AS), SC1 CA182843-07S1, and R01 CA175370 (AS). PLT is an M.D./Ph.D. candidate supported by NIH grant S21MD000104. SDW is a Ph.D. candidate supported by NIH RISE Grant R25GM59994.

Conflict of interest

The authors declare no conflict of interest.

Data accessibility

Data will be available from the corresponding author upon request.

Author contributions

PLT, GN, and JO conceived, designed, performed experiments, analyzed data, and wrote the manuscript; PLT and GN contributed equally to this work. TR, AE, SW, and DC performed experiments; AS and AMS provided new tools and reagents and supervised the study.
References

1. Schäfer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T and Jahnhen-Dechent W (2003) The serum protein alpha-2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. *J Clin Invest* **112**, 357–366.

2. Mintz PJ, Rietz AC, Cardo-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL *et al.* (2015) Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. *Proc Natl Acad Sci USA* **112**, 2515–2520.

3. Kundra MN, Henderson M, Carter KJ, Gorden L, Binhazim A, Ray S, Baptiste T, Shokrani M, Leite-Browning ML, Jahnhen-Dechent W *et al.* (2010) Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer. *Am J Pathol* **177**, 2635–2644.

4. Guillory B, Sakwe AM, Saria M, Thompson P, Adhiambo C, Koumangoye R, Ballard B, Binhazim A, Cone C, Jahnhen-Dechent W *et al.* (2010) Impact of fetuin-A (AHSG) on tumor progression and type 2 diabetes. *Int J Mol Sci* **19**, 2211.

5. Kroger J, Meidtner K, Stefan N, Guevara M, Kerrison ND, Ardanaz E, Aune D, Boeing H, Dorronsoro M, Dow C *et al.* (2018) Circulating fetuin-A and risk of type 2 diabetes: a mendelian randomization analysis. *Diabetes* **67**, 1200–1205.

6. Priya E, Jayashree K, Senthilkumar GP, Yasir M, Babu KR and Devi TD (2019) Role of fetuin-A and vascular endothelial growth factor In type 2 diabetes mellitus patients without and with retinopathy. *Diabetes Metab Syndr* **13**, 2699–2703.

7. Mori K, Emoto M and Inaba M (2011) Fetuin-A: a multifunctional protein. *Recent Pat Endocr Metab Immune Drug Discov* **5**, 124–146.

8. Nangami G, Koumangoye R, Shawn Goodwin J, Sakwe AM, Marshall D, Higginbotham J and Ochieng J (2014) Fetuin-A associates with histones intracellularly and shuttles them to exosomes to promote focal adhesion assembly resulting in rapid adhesion and spreading in breast carcinoma cells. *Exp Cell Res* **328**, 388–400.

9. Watson K, Koumangoye R, Thompson P, Sakwe AM, Patel T, Pratap S and Ochieng J (2012) Fetuin-A triggers the secretion of a novel set of exosomes in detached tumor cells that mediate their adhesion and spreading. *FEBS Lett* **586**, 3458–3463.

10. Nangami GN, Sakwe AM, Izban MG, Rana T, Lammers PE, Thomas P, Chen Z and Ochieng J (2016) Fetuin-A (alpha2HS glycoprotein) modulates growth, motility, invasion, and senescence in high-grade astrocytomas. *Cancer Med* **5**, 3532–3543.

11. Sakwe AM, Koumangoye R, Goodwin SJ and Ochieng J (2010) Fetuin-A (alpha2HS-glycoprotein) is a major serum adhesion protein that mediates growth signaling in breast tumor cells. *J Biol Chem* **285**, 41827–41835.

12. Chen NX, O’Neill KD, Chen X, Duan D, Wang E, Sturek MS, Edwards J and Moe SM (2007) Fetuin-A uptake in bovine vascular smooth muscle cells is calcium dependent and mediated by annexins. *Am J Physiol Renal Physiol* **292**, F599–F606.

13. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS and Bhattacharya S (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. *Nat Med* **18**, 1279–1285.

14. Lien E, Means TK, Heine H, Yoshimura A, Kusumoto S, Fukase K, Fenton MJ, Okawa M, Qureshi N, Monks B *et al.* (2000) Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. *J Clin Invest* **105**, 497–504.

15. McGee A and O’Neill LA (2010) Localisation and trafficking of Toll-like receptors: an important mode of regulation. *Curr Opin Immunol* **22**, 20–27.

16. Schilling JD, Mulvey MA, Vincent CD, Lorenz RG and Hultgren SJ (2001) Bacterial invasion augments epithelial cytokine responses to Escherichia coli through a lipopolysaccharide-dependent mechanism. *J Immunol* **166**, 1148–1155.

17. Tan Y, Zanoni I, Cullen TW, Goodman AL and Kagan JC (2015) Mechanisms of Toll-like receptor 4 endocytosis reveal a common immune-evasion strategy used by pathogenic and commensal bacteria. *Immunity* **43**, 909–922.

18. Mehmeti M, Allauoi R, Bergenfelz C, Saal LH, Ether SP, Johansson ME, Jirström K and Leandersson K (2015) Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. *Breast Cancer Res* **17**, 130.
22 Braunstein MJ, Kucharczyk J and Adams S (2018) Targeting Toll-like receptors for cancer therapy. Target Oncol 13, 583–598.
23 Messaritakis I, Stogiannitsi M, Koulouridi A, Sfakianaki M, Voutsina A, Sotiriou A, Athanasakis E, Xynos E, Mavroudis D, Tzardi M et al. (2018) Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PLoS One 13, e0197327.
24 Ochieng J, Nangami G, Sakwe A, Rana T, Ingram S, Goodwin JS, Moye C, Lammers P and Adunyah SE (2018) Extracellular histones are the ligands for the uptake of exosomes and hydroxyapatite-nanoparticles by tumor cells via syndecan-4. FEBS Lett 592, 3274–3285.
25 Janardhan KS, McIsaac M, Fowlie J, Shrivastav A, Caldwell S, Sharma RK and Singh B (2006) Toll like receptor-4 expression in lipopolysaccharide induced lung inflammation. Histol Histopathol 21, 687–696.
26 Koumangoye RB, Sakwe AM, Goodwin JS, Patel T and Ochieng J (2011) Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS One 6, e24234.
27 Fisher HW, Puck TT and Sato G (1958) Molecular growth requirements of single mammalian cells: the action of fetuin in promoting cell attachment to glass. Proc Natl Acad Sci USA 44, 4–10.
28 Rizzino A and Sato G (1978) Growth of embryonal carcinoma cells in serum-free medium. Proc Natl Acad Sci USA 75, 1844–1848.
29 Brown WM, Saunders NR, Mollgard K and Dziegielewska KM (1992) Fetuin–an old friend revisited. BioEssays 14, 749–755.
30 Makkar S, Riehl TE, Chen B, Yan Y, Alvarado DM, Ciorba MA and Stenson WF (2019) Hyaluronic acid binding to TLR4 promotes proliferation and blocks apoptosis in colon cancer. Mol Cancer Ther 18, 2446–2456.
31 Ahmed A, Redmond HP and Wang JH (2013) Links between Toll-like receptor 4 and breast cancer. Oncoimmunology 2, e22945.
32 Akutekwe A, Seker H and Yang S (2015) In silico discovery of significant pathways in colorectal cancer metastasis using a two-stage optimisation approach. IET Syst Biol 9, 294–302.
33 Zografos E, Anagnostopoulos AK, Papadopoulou A, Legaki E, Zagouri F, Marinos E, Tsangaris GT and Gazouli M (2019) Serum proteomic signatures of male breast cancer. Cancer Genomics Proteomics 16, 129–137.
34 Nangami GN, Watson K, Parker-Johnson K, Okereke KO, Sakwe A, Thompson P, Frimpong N and Ochieng J (2013) Fetuin-A (alpha2HS-glycoprotein) is a serum chemo-attractant that also promotes invasion of tumor cells through Matrigel. Biochem Biophys Res Commun 438, 660–665.